News | February 19, 2026
Axol Bioscience acquires ophthalmology business from Newcells Biotech
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
This transaction fundamentally strengthens Scinai's CDMO platform
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Subscribe To Our Newsletter & Stay Updated
